Vertex Pharmaceuticals: Company Passes My Health Check With Flying Colors, Upholding Buy Rating
Vertex Pharmaceuticals Incorporated's stock has shown resilience, recovering from dips and maintaining a strong long-term growth trajectory, driven by its robust CF franchise and new product approvals. The company's 2024 performance was solid, with TRIKAFTA/KAFTRIO generating >$10bn revenues, and 2025 guidance suggesting continued growth despite some challenges. Vertex's diversification efforts include the approval of pain therapy JOURNAVX and gene therapy Casgevy, with potential multi-billion-dollar revenue contributions from these and other pipeline drugs.
Trade Tracker: Rob Sechan sells McDonald's and Vertex, buys Texas Pacific Land, Amgen and NRG
Rob Sechan, CEO of NewEdge Wealth, joins CNBC's "Halftime Report" to detail his many portfolio moves.
Vertex, Inc. (VERX) Q4 2024 Earnings Call Transcript
Vertex, Inc. (NASDAQ:VERX ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Joe Crivelli – Vice President of Investor Relations David DeStefano – President and Chief Executive Officer John Schwab – Chief Financial Officer Conference Call Participants Rob Oliver – Baird Chris Quintero – Morgan Stanley Joshua Reilly – Needham Samad Samana – Jefferies Steve Enders – Citi Daniel Jester – BMO Capital Markets Jacob Roberge – William Blair Alex Sklar – Raymond James Patrick Walravens – Citizens William Jellison – D.A. Davidson Adam Hotchkiss – Goldman Sachs Operator Good morning and welcome to the Vertex Incorporated Fourth Quarter 2024 Earnings Conference Call.
Here's What Key Metrics Tell Us About Vertex (VERX) Q4 Earnings
The headline numbers for Vertex (VERX) give insight into how the company performed in the quarter ended December 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Vertex (VERX) Tops Q4 Earnings and Revenue Estimates
Vertex (VERX) came out with quarterly earnings of $0.15 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.13 per share a year ago.
Vertex to Report Q4 Earnings: What's in Store for the Stock?
VERX's fourth-quarter 2024 performance is likely to have benefited from the growing adoption of cloud-based tax automation solutions.
Countdown to Vertex (VERX) Q4 Earnings: Wall Street Forecasts for Key Metrics
Get a deeper insight into the potential performance of Vertex (VERX) for the quarter ended December 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Vertex Pharmaceuticals Gets a Huge FDA Approval Which Could Send the Stock Skyrocketing
Obtaining approval from the U.S. Food and Drug Administration (FDA) for a key medication can be a huge catalyst for a healthcare stock. It opens up new growth opportunities for the business.
Calls of the Day: Charles Schwab, Vertex Pharma and Transocean
The Investment Committee debate the latest Calls of the Day.
Vertex: Strong Sales, Stronger Pipeline
Here's our initial take on Vertex Pharmaceuticals' (VRTX 0.14%) fourth-quarter financial report.
Vertex's Revenue Surges but EPS Slips
Vertex Pharmaceuticals (VRTX 0.14%), known for its innovative treatments, reported its fourth-quarter earnings on Feb. 10. The company's revenue increased significantly to $2.91 billion, which was above analysts' expectations of $2.78 billion.
Vertex Pharmaceuticals' Revenue Forecast Tops Expectations
Vertex Pharmaceuticals (VRTX) reported fourth-quarter revenue and offered an outlook for 2025 that topped analysts' expectations.
